NCT04448223View on ClinicalTrials.gov

A Clinical Study to Evaluate the Efficacy and Safety of CKD-351

PHASE2UnknownINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

June 11, 2020

Primary Completion Date

December 5, 2022

Study Completion Date

December 5, 2022

Conditions
Primary Open Angle GlaucomaOcular Hypertension
Interventions
DRUG

CKD-351

Latanoprost (25ug/ml), Dorzolamide (20mg/ml), twice a day

DRUG

Latanoprost+Dorzolmamide

Latanoprost(50ug/ml) , once a day Dorzolmamide(20mg/ml), threetimes a day

Trial Locations (1)

Unknown

RECRUITING

Seoul National University Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY